Evaluation of the Effectiveness, Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients

A Prospective, Multi-center, Post-marketing Observational Study to Evaluate the Effectiveness and Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients

This is a prospective, multi-center, post-marketing observational study to evaluate the effectiveness and compliance of ibuprofen in a sustained release form in the treatment of Egyptian osteoarthritic patients.

Study Overview

• Status: Completed
• Conditions: Pain; Osteoarthritis; Morning Stiffness

Detailed Description

This was a prospective, longitudinal, multicenter observational study conducted in a clinical practice setting where the study product was used in osteoarthritis patients as indicated in the approved package insert; the dosing regimen of Brufen retard is 2 tablets as a single dose once daily.

• Study Type: Observational
• Enrollment (Actual): 519

Contacts and Locations

Study Locations

• Egypt
  • Alexandria, Egypt
    • Site Reference ID/Investigator# 42584
  • Alexandria, Egypt
    • Site Reference ID/Investigator# 42585
  • Alexandria, Egypt
    • Site Reference ID/Investigator# 42591
  • Alexandria, Egypt
    • Site Reference ID/Investigator# 42593
  • Alexandria, Egypt
    • Site Reference ID/Investigator# 42594
  • Cairo, Egypt
    • Site Reference ID/Investigator# 29755
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42582
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42583
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42586
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42587
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42588
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42589
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42590
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42592
  • Cairo, Egypt
    • Site Reference ID/Investigator# 42595

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Primary care clinics

Description

Inclusion Criteria:

• Patients seeking treatment for osteoarthritis and there are clinical or radiological evidence of the disease,
• Male or female, age ≥ 18
• Designated to treatment with Ibuprofen in a sustained release form (Brufen Retard) according to the best criterion of the physician and if he decides to treat the patient according to labeled indication and dose for 4 weeks.
• Patients who have given their written informed consent to participate in the study
• Patients who are currently taking non steroidal anti inflammatory drugs (NSAIDs), should complete an initial washout phase 10 days depending on the half life of the drug taken

Exclusion Criteria:

• Contraindications as described in company core data sheet (CCDS) and specifically
• Patients with active peptic ulcer
• Patients who have presented reactions of hypersensitivity (asthma , rhinitis or urticaria ) with ibuprofen or other anti-inflammatory non steroids
• Patients with active cardiovascular disease and those taking aspirin/warfarin for prophylaxis for myocardial infarction (MI) or stroke
• Patients with moderate to severe renal diseases
• Patients with moderate to severe hepatic disease
• Patients with Crohn's disease
• Patients included currently in another study
• Women of childbearing potential must not be pregnant
• Any patients the investigators consider ineligible for this study

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Osteoarthritic patients; Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Day and Night Mean Pain Score for the Previous 24 Hours on a Nine-point Scale (0 = no Pain to 8 = Very Severe Pain) at Visit 3 (4 Weeks Following Treatment) in Comparison to Baseline.	Scoring of day and night pain for the previous 24 hours was performed on a nine-point scale (0 = no pain to 8 = very severe pain) at each visit and compared to baseline. The overall mean pain score was calculated for participants who completed the study at each visit.	Baseline and 4 weeks
Number of Participants Who Improved (Reduced Pain), Had no Change (Equal Scores at Baseline and Visit), and Worsened (Increased Pain) at Visit 3 (After 4 Weeks of Treatment).	Scoring of day and night pain for the previous 24 hours was performed on a 9-point scale (0 = no pain to 8 = very severe pain) at each visit. The number of participants at Visit 3 (after 4 weeks of treatment) who improved (had reduced pain; from higher baseline score to lower Visit 3 score), had no change (equal scores at baseline and Visit 3), and worsened (increased pain; from lower baseline score to higher Visit 3 score) was calculated.	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of Participant Compliance	The frequency with which the participant forgot to take treatment or changed dose/administration was determined by comparing the actual number of tablets taken by the participant to the scheduled number of tablets since the last visit. Results are presented in percent (0 - 100% scale, with 100% being perfect compliance and 0% being no compliance at all).	2 and 4 weeks
Number of Participants With Joint Tenderness/Stiffness at Each Visit	Joint tenderness/stiffness was measured using a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) at each visit.	Baseline, 2 weeks, and 4 weeks
Number of Participants Who Improved (Reduced), Had no Change (Equal at Baseline and Visit), and Worsened (Increased) in Joint Tenderness/Stiffness at Visit 2 (After 2 Weeks of Treatment) and Visit 3 (After 4 Weeks of Treatment).	Duration of morning stiffness at each visit was assessed and the number of participants who improved, had no change, or worsened at each visit, following 2 and 4 weeks of treatment (Visit 2 and Visit 3, respectively) was calculated.	2 and 4 weeks
Duration of Morning Stiffness	The duration of morning stiffness in minutes was assessed at each visit.	Baseline, 2 weeks, and 4 weeks
Number of Participants With 80% Reduction From Baseline in Duration of Morning Stiffness at Visit 2 (2 Weeks of Treatment) and Visit 3 (4 Weeks of Treatment)	The number of participants who achieved an 80% reduction from baseline in morning stiffness was calculated at each visit.	2 and 4 weeks
Number of Participants With the Ability to Carry Out Normal Activities at Each Visit	The number of participants who were able or unable to carry out normal activities was assessed at each visit.	Baseline, 2 weeks, and 4 weeks
Number of Participants Who Experienced Adverse Events and Serious Adverse Events	Tolerability was assessed by collecting adverse events during the course of the study up to 30 days following the last dose of Brufen Retard. The number of participants experiencing a serious or non-serious adverse event is summarized. See the Reported Adverse Event section for details.	Baseline to 4 weeks

Collaborators and Investigators

• Sponsor: Abbott
• Collaborators: Clintek
• Investigators: Study Director: Rasha Eldessouky, MBBC, Abbott (Egypt)

Study record dates

Study Major Dates

• Study Start: June 1, 2010
• Primary Completion (Actual): November 1, 2010
• Study Completion (Actual): November 1, 2010

Study Registration Dates

• First Submitted: September 7, 2010
• First Submitted That Met QC Criteria: October 20, 2010
• First Posted (Estimate): October 21, 2010

Study Record Updates

• Last Update Posted (Estimate): September 20, 2013
• Last Update Submitted That Met QC Criteria: September 16, 2013
• Last Verified: January 1, 2012

More Information

Terms related to this study

• Keywords: Osteoarthritis; Pain; Morning stiffness
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis
• Other Study ID Numbers: P12-162